Considering the role of H4K16ac modification in promoting promoter activation by regulating nucleosome accessibility and its involvement in the epigenetic regulation of metabolic disorders,29 we hypothesized that H4K16ac modification might direct SLC9A6‐126aa to regulate CD36 transcription. This evidence concerns the gene SLC9A6 and metabolic disease.